How should an adult patient with normal renal function who is taking gabapentin 900 mg three times daily be transitioned to pregabalin (Lyrica)?

Transitioning from Gabapentin to Pregabalin

For a patient taking gabapentin 900 mg three times daily (2700 mg/day total) with normal renal function, transition to pregabalin 450 mg/day (225 mg twice daily) using either immediate discontinuation or a brief overlap approach.

Dose Conversion Ratio

• Use a 6:1 conversion ratio (gabapentin to pregabalin) when transitioning between these medications. 1
• For gabapentin 2700 mg/day, the equivalent pregabalin dose is 450 mg/day (2700 ÷ 6 = 450). 1
• This 6:1 ratio has been validated in clinical practice and maintains comparable analgesic efficacy. 1

Transition Methods

Option 1: Immediate Discontinuation (Preferred for Simplicity)

• Stop gabapentin completely and start pregabalin 150 mg twice daily (300 mg/day) at the next scheduled dose. 2, 3
• Pharmacokinetic modeling demonstrates that pregabalin-equivalent concentrations remain stable during immediate transition, with therapeutic levels achieved within 1 day of pregabalin initiation. 3
• After 1 week, increase to the target dose of 225 mg twice daily (450 mg/day) based on efficacy and tolerability. 2

Option 2: Gradual Overlap

• Day 1-4: Reduce gabapentin to 50% of current dose (450 mg three times daily = 1350 mg/day) while simultaneously starting pregabalin at 50% of target dose (75 mg twice daily = 150 mg/day). 3
• Day 5 onward: Discontinue gabapentin completely and increase pregabalin to 150 mg twice daily (300 mg/day). 2, 3
• After 1 week: Titrate to target dose of 225 mg twice daily (450 mg/day) if needed. 2
• Pharmacokinetic simulations show pregabalin-equivalent concentrations remain stable with this approach, reaching therapeutic pregabalin levels within 1 day of gabapentin cessation. 3

Dosing Schedule Considerations

• Pregabalin requires only twice-daily dosing compared to gabapentin's three-times-daily requirement, improving adherence. 2
• The maximum recommended pregabalin dose is 600 mg/day; doses above 450 mg/day show no additional benefit and increased adverse effects. 2
• Unlike gabapentin, pregabalin has linear pharmacokinetics and does not require the strict scheduled dosing intervals that gabapentin demands. 4, 2

Monitoring and Titration

• Assess response after 2-3 weeks at the maintenance dose before considering further dose adjustments. 2
• If inadequate pain relief persists at 450 mg/day, pregabalin may be increased to a maximum of 300 mg twice daily (600 mg/day), though this higher dose is less well tolerated. 2
• Monitor for side effects including dizziness, somnolence, and peripheral edema (which occurs more frequently with pregabalin than gabapentin). 1

Important Caveats

• The FDA label explicitly states that "the efficacy of add-on pregabalin in patients taking gabapentin has not been evaluated in controlled trials," so prolonged co-administration is not recommended. 2
• Both transition methods produce comparable outcomes in pharmacokinetic modeling, so choose based on patient-specific factors such as anxiety about medication changes or history of withdrawal symptoms. 3
• Patients may report faster onset and longer duration of action with pregabalin compared to gabapentin, though individual responses vary. 1
• If the patient has any degree of renal impairment, dose adjustments are mandatory for both medications, as both are primarily renally excreted. 2, 5